Bill Haney, Dragonfly CEO (Getty Images)
Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology — with a potential IL-12 game-changer
In the oncology R&D world, IL-12 has a rep something akin to nitroglycerine in old Hollywood movies. It’s incredibly powerful, but any false move and … kaboom.
You’re dead.
That makes it the perfect kind of target for drug hunters who like a big challenge, particularly when you’re using it to orchestrate an immune response in a tumor — the classic Holy Grail in these post-PD-(L)1 approval days as investigators try to stack immuno-oncology strategies. And nobody knows that better than Bristol Myers Squibb, which has two of the original checkpoint stars in the portfolio.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
